Europe Collaborates on Generic Drugs
The European Medicines Agency plans on sharing generic-drug assessment reports with regulators outside the European Union.
As part of the International Generic Drug Regulators Pilot (IGDRP), the European Medicines Agency (EMA) is providing the agency’s assessments of applications for generic medicines in real time with collaborating regulatory agencies outside the European Union (EU). EMA is sharing the assessments as part of an information-sharing initiative to ensure timely authorization and availability of generic drugs.
IGDRP was started in July 2014 using the EU-decentralized procedure as a model, and it is now extended to the centralized procedure. According to the EMA, the aim of the pilot is to “both save global assessment resources and to facilitate and strengthen the scientific assessment process for medicines. It is expected that this sharing of assessments will allow authorization of generic products in concerned countries in a coordinated and resource effective way.”
Source: European Medicines Agency
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
